ALK

Results: 294



#Item
111NO 2041 ALK  DIRECTION GÉNÉRALE DES FINANCES PUBLIQUES  nO #10

NO 2041 ALK DIRECTION GÉNÉRALE DES FINANCES PUBLIQUES nO #10

Add to Reading List

Source URL: www.impots.gouv.fr

Language: French - Date: 2015-04-10 09:54:01
    112Allgemeine Verkaufs- und Lieferbedingungen für Arzneimittel der ALK-Abelló Arzneimittel GmbH 1.	 Allgemeines 1. 1	Mit der Erteilung des Auftrages erkennt der Käufer unsere ­All­gemeinen Verkaufs- und Lieferbedingun

    Allgemeine Verkaufs- und Lieferbedingungen für Arzneimittel der ALK-Abelló Arzneimittel GmbH 1. Allgemeines 1. 1 Mit der Erteilung des Auftrages erkennt der Käufer unsere ­All­gemeinen Verkaufs- und Lieferbedingun

    Add to Reading List

    Source URL: www.milbencheck.at

    Language: German - Date: 2014-10-17 07:14:47
      113hydrogen - A Competitive Energy Storage Medium To Enable the Large Scale Integration of Renewable Energies Seville, 15-16 November[removed]H2 from RES: pressurised alk. electrolyser with high efficiency and wide operating

      hydrogen - A Competitive Energy Storage Medium To Enable the Large Scale Integration of Renewable Energies Seville, 15-16 November[removed]H2 from RES: pressurised alk. electrolyser with high efficiency and wide operating

      Add to Reading List

      Source URL: www.iphe.net

      Language: English - Date: 2012-11-26 15:34:04
      114Lung cancer / Organofluorides / Organochlorides / Anatomical pathology / Crizotinib / Pyrazoles / Non-small-cell lung carcinoma / Anaplastic lymphoma kinase / ALK inhibitor / Medicine / Chemistry / Oncology

      Public Summary Document Application No[removed] – Testing of the anaplastic lymphoma kinase (ALK) gene in patients with non–small cell lung cancer to determine eligibility for treatment with crizotinib

      Add to Reading List

      Source URL: www.msac.gov.au

      Language: English - Date: 2015-04-16 01:23:53
      115Vesalius SCALpel™ : Liver Physiology alk phos from ductal membrane, increased in obstruction fasting glucose from gluconeogenesis from alanine and lactate not from glycolysis Kupfer cells/RES (liver, spleen, lung) clea

      Vesalius SCALpel™ : Liver Physiology alk phos from ductal membrane, increased in obstruction fasting glucose from gluconeogenesis from alanine and lactate not from glycolysis Kupfer cells/RES (liver, spleen, lung) clea

      Add to Reading List

      Source URL: www.vesalius.com

      Language: English - Date: 2009-04-06 14:38:34
      11613163 CONCEPT Area A March 2014.indd

      13163 CONCEPT Area A March 2014.indd

      Add to Reading List

      Source URL: www.katanning.wa.gov.au

      Language: English - Date: 2014-08-14 03:20:02
      117Microsoft Word[removed]FinalPSD-ALKtestingforcrizotinib-Nov2014update-accessible.DOCX

      Microsoft Word[removed]FinalPSD-ALKtestingforcrizotinib-Nov2014update-accessible.DOCX

      Add to Reading List

      Source URL: www.msac.gov.au

      Language: English - Date: 2015-04-16 01:23:53
      118Microsoft Word - ALKsxann[removed]CI ALK Company Update on Solid Progress

      Microsoft Word - ALKsxann[removed]CI ALK Company Update on Solid Progress

      Add to Reading List

      Source URL: www.alkane.com.au

      Language: English - Date: 2015-02-11 20:53:22
        119ACTIVITY OF THE HSP90 INHIBITOR, AT13387, IN ALK-DRIVEN TUMOR MODELS. Nicola Wallis, Tomoko Smyth, Joanne Munck, Ana Rodriguez-Lopez, Victoria Lock, Rachel McMenamin, Neil Thompson & John Lyons Astex Pharmaceuticals, 436

        ACTIVITY OF THE HSP90 INHIBITOR, AT13387, IN ALK-DRIVEN TUMOR MODELS. Nicola Wallis, Tomoko Smyth, Joanne Munck, Ana Rodriguez-Lopez, Victoria Lock, Rachel McMenamin, Neil Thompson & John Lyons Astex Pharmaceuticals, 436

        Add to Reading List

        Source URL: astx.com

        Language: English - Date: 2012-12-17 16:09:22
        120THE HSP90 INHIBITOR, AT13387, IS EFFECTIVE IN MUTANT EGFR AND ALK-POSITIVE NSCLC MODELS. Tomoko Smyth, Ana Rodriguez-Lopez, Rachel McMenamin, Victoria Lock, Jayne Curry, Brent Graham, John Lyons, Neil Thompson and Nicola

        THE HSP90 INHIBITOR, AT13387, IS EFFECTIVE IN MUTANT EGFR AND ALK-POSITIVE NSCLC MODELS. Tomoko Smyth, Ana Rodriguez-Lopez, Rachel McMenamin, Victoria Lock, Jayne Curry, Brent Graham, John Lyons, Neil Thompson and Nicola

        Add to Reading List

        Source URL: astx.com

        Language: English